30.10
-0.34 (-1.12%)
| 前收盘价格 | 30.44 |
| 收盘价格 | 30.39 |
| 成交量 | 357,718 |
| 平均成交量 (3个月) | 433,247 |
| 市值 | 970,731,008 |
| 市盈率 (P/E TTM) | 12.86 |
| 预期市盈率 (P/E Forward) | 4.76 |
| 价格/销量 (P/S) | 2.30 |
| 股市价格/股市净资产 (P/B) | 4.15 |
| 52周波幅 | |
| 利润日期 | 20 Feb 2025 - 24 Feb 2025 |
| 营业毛利率 | 14.78% |
| 营业利益率 (TTM) | 35.17% |
| 稀释每股收益 (EPS TTM) | 2.34 |
| 季度收入增长率 (YOY) | 16.50% |
| 季度盈利增长率 (YOY) | -54.80% |
| 总债务/股东权益 (D/E MRQ) | 373.23% |
| 流动比率 (MRQ) | 0.970 |
| 营业现金流 (OCF TTM) | 193.67 M |
| 杠杆自由现金流 (LFCF TTM) | 324.09 M |
| 资产报酬率 (ROA TTM) | 9.67% |
| 股东权益报酬率 (ROE TTM) | 42.89% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Collegium Pharmaceutical, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.50 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 1.64% |
| 机构持股比例 | 122.05% |
| 52周波幅 | ||
| 中 | 37.00 (22.92%) | |
| 总计 | 1 保留 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 11 Oct 2024 | 37.00 (22.92%) | 保留 | 37.72 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2024 | 公告 | Collegium to Participate in Upcoming Investor Conferences |
| 07 Nov 2024 | 公告 | Collegium Reports Record Third Quarter 2024 Financial Results |
| 07 Nov 2024 | 公告 | Collegium Appoints Vikram Karnani as Chief Executive Officer |
| 24 Oct 2024 | 公告 | Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合